A U.S. Centers for Disease Control and Prevention team has found a significant decrease in the number of rotavirus-related hospitalizations with routine use of GlaxoSmithKline ($GSK) and Merck's ($MRK) rotavirus vaccines in older age groups.
Norovirus has replaced rotavirus as the most common cause of acute infectious gastroenteritis in children in the U.S., a testament to the success of GlaxoSmithKline and Merck vaccines in stopping the spread of rotavirus. Development of a shot for norovirus is lagging behind, though.
Having committed to offering its rotavirus vaccine--Rotavac--for $1 a dose in 2011, Indian vaccine manufacturer Bharat Biotech has now presented positive Phase III data that compares favorably to currently available rotavirus vaccines.
British health officials selected GlaxoSmithKline's Rotarix vaccine for the country's first routine rotavirus immunization program.
About 700,000 children in the Philippines will receive a rotavirus vaccination, thanks to a national immunization program for children.
Rwanda's government has launched a national rotavirus vaccination program using Merck's RotaTeq oral rotavirus vaccine. The program will include all infants in the country, meaning that over 100,000 children will get the vaccine before the end of 2012.
The deal cuts the price for the vaccines 67 percent and means vaccines for 70 million children in the world's 40 poorest countries by 2016.
A new oral vaccine from Australia could help to cut deaths from rotavirus infections, in the developing as well as the developed world.
In the past, vaccines against rotavirus, an infection causing severe diarrhea, have been linked with serious bowel problems and blockages in infants, but a large-scale study of over three-quarters of
Researchers have found that vaccinating infants against rotavirus may help protect the unvaccinated children and adults around them. In a Centers for Disease Control and Prevention study published in